Pfizer Creates “More Adversarial” Government Investigations Group
This article was originally published in The Pink Sheet Daily
Executive Summary
Separate from the compliance counsel, the newly formed government investigations group allows Pfizer “to become more adversarial from the government investigations standpoint,” Assistant General Counsel Lankler says. The team is part of Pfizer’s litigation office.
You may also be interested in...
Pfizer Will Monitor Off-Label Drug Use And Report To IG Under Neurontin Settlement
Corporate integrity agreement will be carefully studied in pharmaceutical industry given uncertainties surrounding off-label promotion rules. Pfizer agrees to establish clear policies and keep close tabs on off-label use – but the agreement does not define prohibited or permitted activities.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.